General Information of Drug (ID: DM0K4DZ)

Drug Name
BMS-182657 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Terminated [1]
Cross-matching ID
PubChem CID
9801007
TTD Drug ID
DM0K4DZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Neutral endopeptidase (MME)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LCZ696 DMLFX7K Heart failure BD10-BD13 Approved [2]
Candoxatril DMHJCGV Hypertension BA00-BA04 Phase 3 [3]
Gallopamil DMXBR27 Asthma CA23 Phase 2 [4]
SLV 306 DMCDON3 Acute decompensated heart failure BD1Z Phase 2 [5]
SLV-334 DMXCJKY Brain injury NA07.Z Phase 2 [6]
VX-15 DMLWM4G Huntington disease 8A01.10 Phase 2 [7]
Sampatrilat DMXTOVE Hypotension BA20-BA21 Phase 2 [8]
SLV-338 DM7WKTM Cardiovascular disease BA00-BE2Z Phase 1 [9]
GW-796406 DMQ46DN Hypotension BA20-BA21 Phase 1 [4]
Debio 0827 DMQIEFB Chronic pain MG30 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enalapril DMNFUZR Congestive heart failure BD10 Approved [11]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [12]
Captopril DM458UM Chronic heart failure BD1Z Approved [13]
Benazepril DMH1M9B Hypertension BA00-BA04 Approved [14]
Moexipril DM26E4B Hypertension BA00-BA04 Approved [15]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [16]
Perindopril DMOPZDT Hypertension BA00-BA04 Approved [17]
Trandolapril DM4L6EU Chronic heart failure BD1Z Approved [18]
Fosinopril DM9NJ52 Chronic heart failure BD1Z Approved [19]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Modulator [1]
Neutral endopeptidase (MME) TT5TKPM NEP_HUMAN Modulator [1]

References

1 Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
4 Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
5 The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
6 Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
9 Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
10 Clinical pipeline report, company report or official report of Debiopharm (2011).
11 Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
12 Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
13 Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
14 Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
15 Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
16 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
17 Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
18 Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
19 Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
20 Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.